OncoMed is developing several compounds that target Wnt and Notch pathways, which are important in cancer and cancer stem cell maintenance, survival, and proliferation. Biomarkers for response of Her-2-negative breast cancer and non-small cell lung cancer (NSCLC) following treatment with Vantictumab, anti-Wnt monoclonal antibody, have been developed. Continue reading
Tag Archives: stem cells
Targeting Cancer Stem Cells – OncoMed’s R-SPONDIN LGR Antibody for Colorectal Cancer
OncoMed initiated a Phase I/II trial of its anti-RSPO3 antibody (OMP-131R10) in patients with relapsed colorectal cancer. Patients will also be receiving FOLFIRI (5-FU, irinotecan, leucovorin). Continue reading